CD-19抗体の世界市場レポート 2025年

CD-19抗体市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.0％で27億米ドルに成長します。予測期間中の成長は、標的がん治療に対する需要の増加、スマート細胞療法の採用増加、血液悪性腫瘍の有病率の上昇、新興国市場での医療アクセスの拡大、次世代免疫療法の開発、生物製造技術の強化などが背景にあります。この時期の主な動向としては、抗体薬物複合体の進歩、二重特異性抗体の開発、抗体設計へのAIの統合、細胞-細胞療法プラットフォームの改善、シングルユース・バイオリアクターの採用、ナノボディベースの治療薬の出現、生物製剤製造の自動化などが挙げられます。

B細胞性悪性腫瘍の有病率の増加がCD19抗体市場の成長を牽引すると予想されます。B細胞悪性腫瘍は、B細胞リンパ腫や白血病など、異常なBリンパ球に由来する一群のがんを包含し、免疫系に影響を及ぼし、制御不能な細胞増殖をもたらします。これらの悪性腫瘍の有病率の上昇には、集団の高齢化、遺伝的素因、環境暴露、ライフスタイルの変化、検出法の進歩、免疫系の変化など、いくつかの要因が関与しています。CD19抗体は、B細胞悪性腫瘍の治療において、悪性B細胞上に存在するCD19タンパク質を特異的に標的とし、健康な細胞を温存して免疫反応を高める一方で、悪性B細胞を効果的に破壊することにより、重要な役割を果たしています。例えば、2024年1月、米国がん協会は、米国で約8万620人が非ホジキンリンパ腫と診断され、推定2万240人が死亡すると報告しました。その結果、B細胞性悪性腫瘍の罹患率の増加がCD19抗体市場の拡大に拍車をかけています。

CD19抗体市場の主要企業は、特に血液悪性腫瘍に対するがん治療効果を向上させるため、遺伝子組み換え自己T細胞免疫療法などの技術革新に注力しています。この治療法では、患者のT細胞を遺伝子工学的に操作してがん細胞を認識・攻撃させてから体内に再導入し、免疫反応を高める。例えば、2024年11月、米国を拠点とするバイオ医薬品会社オートラス・セラピューティクスplcは、再発または難治性のB細胞前駆体急性リンパ芽球性白血病（ALL）の成人患者を治療するためのAUCATZYL（オベカブタジーン・オートリューセル）のFDA承認を取得しました。この治療は、毒性を最小限に抑え、制御されたT細胞活性化により治療細胞の持続性を改善するように設計されています。投与は1日目と10日目に分割点滴で行われ、投与量は骨髄評価に基づいて個々の患者のニーズに合わせて調整されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界CD-19抗体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のCD-19抗体市場：成長率分析
• 世界のCD-19抗体市場の実績：規模と成長, 2019-2024
• 世界のCD-19抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界CD-19抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のCD-19抗体市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• B細胞非ホジキンリンパ腫
• 慢性リンパ性白血病
• 急性リンパ性白血病
• その他の病気の種類
• 世界のCD-19抗体市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリクローナル
• モノクローナル
• 世界のCD-19抗体市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• 世界のCD-19抗体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素結合免疫吸着法
• フローサイトメトリー
• 免疫組織化学凍結
• 免疫組織化学パラフィン
• その他の用途
• 世界のCD-19抗体市場B細胞性非ホジキンリンパ腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• びまん性大細胞型B細胞リンパ腫（DLBCL）
• 濾胞性リンパ腫
• マントル細胞リンパ腫
• 世界のCD-19抗体市場慢性リンパ性白血病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 再発性または難治性CLL
• 治療未経験のCLL
• 世界のCD-19抗体市場急性リンパ性白血病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• B細胞前駆細胞性ALL
• フィラデルフィア染色体陽性ALL
• 世界のCD-19抗体市場、その他の疾患の種類のサブセグメンテーション、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 有毛細胞白血病
• ワルデンシュトレームマクログロブリン血症
• 辺縁帯リンパ腫

第7章 地域別・国別分析

• 世界のCD-19抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のCD-19抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• CD-19抗体市場：競合情勢
• CD-19抗体市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Bio-Rad Laboratories Inc.
• Miltenyi Biotec GmbH
• Abcam Plc
• Kite Pharma Inc.
• BioLegend Inc.
• Xencor Inc.
• Juno Therapeutics Inc.
• BD Biosciences
• Zenas BioPharma Inc.
• Cell Signaling Technology Inc.
• Santa Cruz Biotechnology Inc.
• Novus Biologicals LLC
• Tonbo Biosciences Inc.
• Bio X Cell Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• CD-19抗体市場2029：新たな機会を提供する国
• CD-19抗体市場2029：新たな機会を提供するセグメント
• CD-19抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

CD19 antibody is a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker primarily found on B cells. CD19 plays a crucial role in B cell development and is often overexpressed in B cell-related malignancies, including certain leukemias and lymphomas. These antibodies are widely used in immunotherapy, particularly in CAR-T cell therapy, to direct the immune system to attack CD19-expressing cancer cells.

The primary disease types in the CD19 antibody market include B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and others. B-cell non-Hodgkin lymphoma originates in B lymphocytes, a type of white blood cell essential for immune defense. CD19 antibodies are classified into polyclonal and monoclonal types, with routes of administration including intravenous and subcutaneous delivery. Their applications span enzyme-linked immunosorbent assay (ELISA), flow cytometry, immunohistochemistry frozen, immunohistochemistry paraffin, and other diagnostic and research uses.

The CD-19 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-19 antibody market statistics, including CD-19 antibody industry global market size, regional shares, competitors with a CD-19 antibody market share, detailed CD-19 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-19 antibody industry. This CD-19 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CD-19 antibody market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the rising prevalence of B-cell malignancies, the increasing adoption of immunotherapy, greater oncology research funding, the emergence of CAR-T cell therapies, heightened healthcare awareness, and the expansion of personalized medicine.

The CD-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.70 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period is driven by the increasing demand for targeted cancer therapies, the rising adoption of smart cell therapies, a higher prevalence of hematologic malignancies, expanded healthcare access in emerging markets, as well as the development of next-generation immunotherapies and enhancements in biomanufacturing technologies. Key trends in this period include advancements in antibody-drug conjugates, the development of bispecific antibodies, the integration of AI into antibody design, improvements in cell-cell therapy platforms, the adoption of single-use bioreactors, the emergence of nanobody-based therapeutics, and the automation of biologics manufacturing.

The increasing prevalence of B-cell malignancies is expected to drive the growth of the CD19 antibody market. B-cell malignancies encompass a group of cancers originating from abnormal B lymphocytes, such as B-cell lymphomas and leukemias, which affect the immune system and lead to uncontrolled cell growth. Several factors contribute to the rising prevalence of these malignancies, including aging populations, genetic predisposition, environmental exposures, lifestyle changes, advancements in detection methods, and immune system alterations. CD19 antibodies play a crucial role in treating B-cell malignancies by specifically targeting the CD19 protein found on malignant B cells, effectively destroying them while sparing healthy cells and boosting the immune response. For example, in January 2024, the American Cancer Society reported that approximately 80,620 people in the U.S. were expected to be diagnosed with non-Hodgkin lymphoma, with an estimated 20,240 deaths. As a result, the growing incidence of B-cell malignancies is fueling the expansion of the CD19 antibody market.

Leading companies in the CD19 antibody market are focusing on technological innovations, such as genetically modified autologous T-cell immunotherapy, to improve cancer treatment effectiveness, particularly for hematologic malignancies. This therapy involves genetically engineering a patient's T cells to recognize and attack cancer cells before reintroducing them into the body to enhance immune response. For instance, in November 2024, Autolus Therapeutics plc, a U.S.-based biopharmaceutical company, received FDA approval for AUCATZYL (obecabtagene autoleucel) for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The treatment is designed to minimize toxicity and improve the persistence of therapeutic cells through controlled T-cell activation. It is administered as a split-dose infusion on days 1 and 10, with dosing tailored to individual patient needs based on bone marrow assessment.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Gracell Biotechnologies Inc. to strengthen its cell therapy pipeline. The acquisition aims to leverage Gracell Biotechnologies' innovative FasTCAR platform and expertise in developing CD19 and BCMA-targeted CAR-T therapies. Gracell Biotechnologies Inc., a China-based clinical-stage biopharmaceutical company, focuses on discovering and developing cutting-edge cell therapies, reinforcing AstraZeneca's commitment to advancing cancer treatment options.

Major players in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

North America was the largest region in the CD-19 antibody market in 2024. The regions covered in CD-19 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD-19 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD-19 antibody market consists of revenues earned by entities by providing monoclonal antibody therapies, CAR-T cell therapies, diagnostic services, biopharmaceutical research and development, and manufacturing services related to the production of CD-19 targeted treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD-19 antibody market includes the sale of recombinant antibodies, and antibody-based therapies targeting CD19 for research and clinical applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD-19 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cd-19 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd-19 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cd-19 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
• 2) By Type: Polyclonal, Monoclonal
• 3) By Route Of Administration: Intravenous, Subcutaneous
• 4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
• Subsegments:
• 1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Mantle Cell Lymphoma
• 2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL; Treatment-Naive CLL
• 3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL; Philadelphia Chromosome-Positive ALL
• 4) By Other Disease Types: Hairy Cell Leukemia; Waldenstrom's Macroglobulinemia; Marginal Zone Lymphoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca plc; Novartis AG; Thermo Fisher Scientific Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. CD-19 Antibody Market Characteristics

3. CD-19 Antibody Market Trends And Strategies

4. CD-19 Antibody Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global CD-19 Antibody Growth Analysis And Strategic Analysis Framework

• 5.1. Global CD-19 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global CD-19 Antibody Market Growth Rate Analysis
• 5.4. Global CD-19 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global CD-19 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global CD-19 Antibody Total Addressable Market (TAM)

6. CD-19 Antibody Market Segmentation

• 6.1. Global CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• B-Cell Non-Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Acute Lymphoblastic Leukemia
• Other Disease Types
• 6.2. Global CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polyclonal
• Monoclonal
• 6.3. Global CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• 6.4. Global CD-19 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Linked Immunosorbent Assay
• Flow Cytometry
• Immunohistochemistry Frozen
• Immunohistochemistry Paraffin
• Other Applications
• 6.5. Global CD-19 Antibody Market, Sub-Segmentation Of B-Cell Non-Hodgkin Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Follicular Lymphoma
• Mantle Cell Lymphoma
• 6.6. Global CD-19 Antibody Market, Sub-Segmentation Of Chronic Lymphocytic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Relapsed Or Refractory CLL
• Treatment-Naive CLL
• 6.7. Global CD-19 Antibody Market, Sub-Segmentation Of Acute Lymphoblastic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• B-Cell Precursor ALL
• Philadelphia Chromosome-Positive ALL
• 6.8. Global CD-19 Antibody Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hairy Cell Leukemia
• Waldenstrom's Macroglobulinemia
• Marginal Zone Lymphoma

7. CD-19 Antibody Market Regional And Country Analysis

• 7.1. Global CD-19 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global CD-19 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific CD-19 Antibody Market

• 8.1. Asia-Pacific CD-19 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China CD-19 Antibody Market

• 9.1. China CD-19 Antibody Market Overview
• 9.2. China CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India CD-19 Antibody Market

• 10.1. India CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan CD-19 Antibody Market

• 11.1. Japan CD-19 Antibody Market Overview
• 11.2. Japan CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia CD-19 Antibody Market

• 12.1. Australia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia CD-19 Antibody Market

• 13.1. Indonesia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea CD-19 Antibody Market

• 14.1. South Korea CD-19 Antibody Market Overview
• 14.2. South Korea CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe CD-19 Antibody Market

• 15.1. Western Europe CD-19 Antibody Market Overview
• 15.2. Western Europe CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK CD-19 Antibody Market

• 16.1. UK CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany CD-19 Antibody Market

• 17.1. Germany CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France CD-19 Antibody Market

• 18.1. France CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy CD-19 Antibody Market

• 19.1. Italy CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain CD-19 Antibody Market

• 20.1. Spain CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe CD-19 Antibody Market

• 21.1. Eastern Europe CD-19 Antibody Market Overview
• 21.2. Eastern Europe CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia CD-19 Antibody Market

• 22.1. Russia CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America CD-19 Antibody Market

• 23.1. North America CD-19 Antibody Market Overview
• 23.2. North America CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA CD-19 Antibody Market

• 24.1. USA CD-19 Antibody Market Overview
• 24.2. USA CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada CD-19 Antibody Market

• 25.1. Canada CD-19 Antibody Market Overview
• 25.2. Canada CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America CD-19 Antibody Market

• 26.1. South America CD-19 Antibody Market Overview
• 26.2. South America CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil CD-19 Antibody Market

• 27.1. Brazil CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East CD-19 Antibody Market

• 28.1. Middle East CD-19 Antibody Market Overview
• 28.2. Middle East CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa CD-19 Antibody Market

• 29.1. Africa CD-19 Antibody Market Overview
• 29.2. Africa CD-19 Antibody Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa CD-19 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa CD-19 Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. CD-19 Antibody Market Competitive Landscape And Company Profiles

• 30.1. CD-19 Antibody Market Competitive Landscape
• 30.2. CD-19 Antibody Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

31. CD-19 Antibody Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Bio-Rad Laboratories Inc.
• 31.3. Miltenyi Biotec GmbH
• 31.4. Abcam Plc
• 31.5. Kite Pharma Inc.
• 31.6. BioLegend Inc.
• 31.7. Xencor Inc.
• 31.8. Juno Therapeutics Inc.
• 31.9. BD Biosciences
• 31.10. Zenas BioPharma Inc.
• 31.11. Cell Signaling Technology Inc.
• 31.12. Santa Cruz Biotechnology Inc.
• 31.13. Novus Biologicals LLC
• 31.14. Tonbo Biosciences Inc.
• 31.15. Bio X Cell Inc.

32. Global CD-19 Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CD-19 Antibody Market

34. Recent Developments In The CD-19 Antibody Market

35. CD-19 Antibody Market High Potential Countries, Segments and Strategies

• 35.1 CD-19 Antibody Market In 2029 - Countries Offering Most New Opportunities
• 35.2 CD-19 Antibody Market In 2029 - Segments Offering Most New Opportunities
• 35.3 CD-19 Antibody Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer